SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Adrian Gottschalk, CEO / Courtesy of Foghorn Thera
Deals
Foghorn Booms onto Nasdaq with $120M IPO
Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece.
October 23, 2020
 · 
2 min read
 · 
Kate Goodwin
Lumasiran is the new hope for Primary Hyperoxaluri
Drug Development
Hope for Primary Hyperoxaluria: Alnylam Shares Positive Trial Results of Lumasiran
Two Phase III studies of lumasiran showed a significant reduction in urinary oxalate excretion in patients of all ages with PH1. Know more about it here.
October 22, 2020
 · 
4 min read
 · 
Kate Goodwin
Deals
Biopharma Money on the Move: October 15-21
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
October 22, 2020
 · 
4 min read
 · 
Kate Goodwin
JHVEPhoto/GettyImages
Lone Star Bio
MD Anderson Brings Underdogs into the Fight Against Cancer with Focus Fund
With an initial capital of $50 million, MD Anderson and partner The Focus Fund hope to invest in small biotechs with big cancer-fighting potential.
October 20, 2020
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Intellia Aims Big with CRISPR Therapy to Cure ATTR
Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR.
October 19, 2020
 · 
3 min read
 · 
Kate Goodwin
Photo Courtesy of Beckman Coulter
Policy
Beckman Coulter Receives Grant to Detect Serious COVID-19 Complication in Kids
The grant was awarded by the U.S. Dept. of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA).
October 16, 2020
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Phase III? What Phase III? Russia Approves Second COVID-19 Vaccine After 100 Person Trial
Putin touts efficacy and safety of new vaccine without the data to back him up.
October 15, 2020
 · 
3 min read
 · 
Kate Goodwin
Business
Merck Plans New Facility to Triple Production of Life-Saving Bladder Cancer Drug
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
October 15, 2020
 · 
2 min read
 · 
Kate Goodwin
Biotech Beach
Biopharma Money on the Move: October 7-14
Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
October 15, 2020
 · 
6 min read
 · 
Kate Goodwin
EdiGene Gets $67 Million Infusion to Bring Gene Editing to the Clinic
The Beijing-based biotech will use the Series B funds to further their hematopoietic disease and cancer therapies pipeline and expand team.
October 13, 2020
 · 
2 min read
 · 
Kate Goodwin
Policy
Professor Charged in Chinese Funds Coverup Case Wants Harvard to Foot His Legal Bill
Charles M. Lieber is currently on paid leave from Harvard’s chemistry department after his arrest in January on charges of lying to the U.S. government about funds received from China.
October 12, 2020
 · 
3 min read
 · 
Kate Goodwin
Business
More Manufacturing, More Jobs - Abzena drops $60 Million on New San Diego Facility
New 50,000-square-foot facility will allow them to expand their services from development and Phase I/II to Phase III and manufacturing.
October 9, 2020
 · 
1 min read
 · 
Kate Goodwin
Drug Development
Amgen & Cytokinetics’ Cardiovascular Drug Disappoints in Phase III
The heart drug met primary endpoint but failed to make the ultimate impact needed.
October 8, 2020
 · 
2 min read
 · 
Kate Goodwin
Policy
FDA Intends to Withdraw Approval of Only Treatment for Reducing Preterm Birth
Makena, the only FDA-approved treatment to reduce preterm birth failed to meet endpoints in a recent trial. The FDA gave notice of intent to withdraw approval.
October 6, 2020
 · 
3 min read
 · 
Kate Goodwin
BioMarin HQ/courtesy of BioMarin
Business
‘Genius’ Kevin Eggan to Lead BioMarin’s Early R&D
Scientific luminary and MacArthur Fellowship winner Kevin Eggan, Ph.D. will lead early-stage research at rare disease-focused BioMarin.
October 5, 2020
 · 
2 min read
 · 
Kate Goodwin
Load More